Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.
1 . A method of treating cancer in a subject in need of such treatment, comprising administering a GLP-1 receptor agonist to the subject.
2 . The method of claim 1 , wherein the GLP-1 receptor agonist is a peptide, polypeptide or protein.
3 . The method of claim 2 , wherein the GLP-1 receptor agonist is a glucagon-like peptide-1 (GLP-1), a derivative of GLP-1, or an analog of GLP-1.
4 . The method of claim 3 , wherein the GLP-1 receptor agonist is GLP(7-36)amide comprising the sequence of SEQ ID NO:1.
5 . The method of claim 3 , wherein the GLP-1 receptor agonist is selected from the group consisting of liraglutide, albiglutide, semaglutide and taspoglutide.
6 . The method of claim 2 , wherein the GLP-1 receptor agonist is exenatide, a derivative of exenatide, or an analog of exenatide.
7 . The method of claim 6 , wherein the GLP-1 receptor agonist is synthetic exenatide peptide comprising the sequence of SEQ ID NO:2.
8 . The method of claim 6 , wherein the GLP-1 receptor agonist is lixisenatide.
9 . The method of claim 1 , wherein the GLP-1 receptor agonist is provided in a suspension formulation comprising:
(a) a particle formulation comprising the GLP-1 receptor agonist; and
(b) a vehicle formulation,
wherein the particle formulation is dispersed in the vehicle.
10 . The method of claim 9 , wherein (a) the particle formulation additionally comprises a disaccharide, methionine and a buffer and (b) the vehicle formulation is a non-aqueous, single-phase suspension vehicle comprising one or more pyrrolidone polymers and one or more solvents selected from the group consisting of lauryl lactate, lauryl alcohol, benzyl benzoate, and mixtures thereof;
wherein the suspension vehicle exhibits viscous fluid characteristics, and the particle formulation is dispersed in the vehicle.
11 . The method of claim 10 , wherein the buffer is selected from the group consisting of citrate, histidine, succinate, and mixtures thereof.
12 . The method of claim 10 , wherein the disaccharide is selected from the group consisting of lactose, sucrose, trehalose, cellobiose, and mixtures thereof.
13 . The method of claim 10 , wherein the particle formulation is a spray dried preparation of particles.
14 . The method of claim 10 , wherein the vehicle consists essentially of polyvinylpyrrolidone and benzyl benzoate.
15 . The method of claim 14 , wherein the vehicle is about 50% solvent and about 50% polymer.
16 . The method of claim 10 , wherein the suspension formulation has an overall moisture content of less than or equal to about 10 wt %.
17 . The method of claim 9 , wherein the CLP-1 receptor agonist is delivered using an implantable osmotic delivery device.
18 . The method of claim 1 , wherein the GLP-1 receptor agonist is provided in an injectable formulation.
19 . The method of claim 1 , wherein one or more beneficial agent in addition to the GLP-1 receptor agonist is delivered to the subject, and the beneficial agent is an anticancer agent, a chemotherapeutic agent, or an antidiabetic agent.
20 . The method of claim 19 , wherein the additional beneficial agent is delivered using an implantable osmotic delivery device.